Advanced Proteome Therapeutics logo

APC - Advanced Proteome Therapeutics Share Price

C$0.075 0.0  0.0%

Last Trade - 11/11/19

Sector
Healthcare
Size
Micro Cap
Market Cap £926k
Enterprise Value £-155k
Revenue £n/a
Position in Universe 2213th / 2609
Bullish
Bearish
Unlock APC Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

APC Revenue Unlock APC Revenue

Net Income

APC Net Income Unlock APC Revenue

Normalised EPS

APC Normalised EPS Unlock APC Revenue

PE Ratio Range

APC PE Ratio Range Unlock APC Revenue

Dividend Yield Range

APC Dividend Yield Range Unlock APC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
APC EPS Forecasts Unlock APC Revenue
Profile Summary

Advanced Proteome Therapeutics Corporation is a biotechnology company. The Company is engaged in the development of anti-cancer therapeutics that exploit the properties of a natural human protein. The Company, through its subsidiary, Advanced Proteome Therapeutics Inc. (APTI), develops and commercializes a new technology platform that is intended for the chemical modification of protein therapeutics. The Foundation Trinity Technology is combining anti-cancer therapies in a single agent for targeted delivery to tumors. It is engaged in targeted therapy, immunotherapy and combination therapy. The Company's technology is applicable to the areas of therapeutics and diagnostics, protein drugs and personalized medicine, and is being applied to cancer therapeutics. It is focusing on enabling technology, designed to link antibodies to drugs or toxins, to produce pure and homogeneous antibody-drug conjugates (ADC).

Directors
Last Annual July 31st, 2018
Last Interim April 30th, 2019
Public Since October 28, 1986
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange TSX Venture Exchange
Shares in Issue 20,998,103
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address 650 Albany St Ste 113, BOSTON, 02118-2518, United States
Web https://www.advancedproteome.com/
Phone +1 617 6380340
Contact ()
Auditors Dale Matheson Carr-Hilton LaBonte LLP
APC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to APC
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.